Evidence map›Paper›PMID 42871296›Full record

ReviewFrontiers in pharmacology2026

Navigating neonatal thrombosis: contemporary insights into a complex disorder in a unique population.

Rozeta Sokou, Vasiliki Mougiou, Alexandra Lianou, Andreas G Tsantes, Stefanos Bonovas, Sotirios P Fortis, Effie G Papageorgiou, Anastasios G Kriebardis, Argirios E Tsantes, Nicoletta Iacovidou

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rozeta SokouNeonatal Department, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Vasiliki MougiouNeonatal Unit, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Alexandra LianouNeonatal Intensive Care Unit, "Aghios Panteleimon" General Hospital of Nikea, Piraeus, Greece.
Andreas G TsantesLaboratory of Haematology and Blood Bank Unit, "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Stefanos BonovasDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Sotirios P FortisLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Bio-Medical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Athens, Greece.
Effie G PapageorgiouLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Bio-Medical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Athens, Greece.
Anastasios G KriebardisLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Bio-Medical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Athens, Greece.
Argirios E TsantesLaboratory of Haematology and Blood Bank Unit, "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Nicoletta IacovidouNeonatal Department, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neonatal thromboembolic disease (TE) is an increasingly recognized clinical condition associated with significant morbidity, despite its relatively low incidence in the general paediatric population. Neonates-especially those in Neonatal Intensive Care Units (NICUs)-are at the highest risk for TE among all paediatric age groups. This elevated risk is attributed to the developmental characteristics of neonatal haemostasis, the frequent use of central venous catheters, and the presence of significant underlying comorbidities. Over recent decades, the reported incidence of neonatal TE has risen significantly, reflecting improvement in neonatal intensive care, and increased awareness and recognition of thrombotic complications. The unique pathophysiology of neonatal TE, and its distinct risk factors, underscore the need for a stronger neonatal-specific evidence to support prevention, diagnosis and management of thromboembolic events. The objective of this review is to summarise and critically appraise existing evidence on the epidemiology, the pathophysiology and the risk factors related to neonatal TE. It also aims to identify current knowledge gaps and areas requiring further investigation. Overall, the available evidence supports a multifactorial model of neonatal thrombosis, whereby developmental hemostasis interacts with acquired antenatal and perinatal risk factors. However, substantial heterogeneity in epidemiological data and diagnostic approaches continues to hinder accurate thrombotic risk stratification and evidence-based clinical decision-making.

Indexed as

developmental hemostasismetabolic healthneonatal thrombotic disordersneonatesthromboembolic diseasethrombosis risk

Identifiers

PMID42871296
PMCPMC13658511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.